SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 2112251

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2112251

Lymphedema Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment Type, By Affected Area, By End-use, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Lymphedema Treatment Market Summary

The global lymphedema treatment market size was valued at USD 8.8 billion in 2025 and is projected to grow from USD 9.5 billion in 2026 to USD 16.6 billion by 2033, at a CAGR of 8.3% from 2026 to 2033. North America held the largest global revenue share of 42.4% in 2025. The growth of the lymphedema treatment industry is driven by the rising prevalence of secondary lymphedema associated with cancer treatments, particularly breast cancer surgeries and radiation therapy, along with growing awareness and earlier diagnosis of the condition.

The increasing adoption of compression therapy products, pneumatic compression devices, and emerging surgical interventions is driving market growth. In addition, expanding healthcare access and ongoing advancements in treatment technologies are improving patient outcomes and creating new opportunities within the market. According to Breastcancer.org, in 2026, it is estimated that about 42,140 women in the U.S. will die from breast cancer, highlighting the continuing mortality burden of the disease despite advances in early detection and treatment.

The rising prevalence of cancer-related lymphedema is a major driver of the lymphedema treatment market, as increasing numbers of cancer survivors require long-term management following lymph node dissection and radiation therapy. Breast cancer patients represent the largest affected group, although lymphedema is also common among survivors of gynecological, prostate, melanoma, and head and neck cancers. Improvements in cancer survival rates have expanded the patient population at risk of developing secondary lymphedema, driving demand for compression therapies, pneumatic compression devices, rehabilitation services, and surgical interventions.

Global Lymphedema Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lymphedema treatment market report based on type, treatment type, affected area, end-use, and region:

  • Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Secondary Lymphedema
    • Cancer-related Lymphedema
    • Non-cancer-related Lymphedema
  • Primary Lymphedema
  • Treatment Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Conservative/Non-invasive Therapy
    • Compression Garments & Stockings
    • Compression Bandages & Wraps
    • Manual Lymphatic Drainage (MLD)
    • Therapeutic Exercise & Complete Decongestive Therapy (CDT)
    • Kinesiology Taping
  • Medical Devices
    • Sequential Pneumatic Compression Devices (SPCDs)
    • Low-Level Laser Therapy (LLLT) Devices
    • Advanced Compression Systems
  • Surgical Interventions
    • Lymphovenous Anastomosis (LVA)
    • Vascularized Lymph Node Transfer (VLNT)
    • Liposuction & Debulking Procedures
  • Pharmacological Therapy
  • Affected Area Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Upper Extremity Lymphedema
  • Lower Extremity Lymphedema
  • Head & Neck Lymphedema
  • Genital & Truncal Lymphedema
  • End-use Outlook (Revenue, USD Million/Billion; 2021 - 2033)
  • Hospitals
  • Lymphedema Treatment Centers & Rehabilitation Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Home Care Settings
  • Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-937-9

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Treatment Type
    • 1.1.3. Affected Area
    • 1.1.4. End Use
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Lymphedema Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Pipeline Analysis
    • 3.2.1. Pipeline products by:
      • 3.2.1.1. Type (biologics, devices)
      • 3.2.1.2. Stage of development
    • 3.2.2. Emerging technologies:
      • 3.2.2.1. Growth factors
      • 3.2.2.2. Stem cell therapy
      • 3.2.2.3. Advanced wound dressings
    • 3.2.3. Innovation trends and approvals
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Rising prevalence of cancer-related lymphedema
      • 3.3.1.2. Increasing cancer survivorship rates
      • 3.3.1.3. Growing awareness and early diagnosis
      • 3.3.1.4. Technological advancements in compression devices
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High treatment costs
      • 3.3.2.2. Shortage of certified lymphedema therapists
    • 3.3.3. Market opportunity analysis
      • 3.3.3.1. Growth in home-based care
      • 3.3.3.2. Expansion in emerging markets
      • 3.3.3.3. Development of smart compression technologies
      • 3.3.3.4. Advances in microsurgical techniques
    • 3.3.4. Market challenge analysis
      • 3.3.4.1. Underdiagnosis and delayed treatment
      • 3.3.4.2. Poor long-term adherence
  • 3.4. Lymphedema Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Bargaining power of suppliers
      • 3.4.1.2. Bargaining power of buyers
      • 3.4.1.3. Threat of substitutes
      • 3.4.1.4. Threat of new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political & Legal Landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological landscape

Chapter 4. Lymphedema Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Lymphedema Treatment: Type Movement Analysis
  • 4.3. Global Lymphedema Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
  • 4.4. Secondary Lymphedema
    • 4.4.1. Secondary lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 4.4.2. Cancer-related lymphedema
      • 4.4.2.1. Cancer-related lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 4.4.3. Non-cancer-related lymphedema
      • 4.4.3.1. Non-cancer-related lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 4.5. Primary Lymphedema
    • 4.5.1. Primary lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 5. Lymphedema Treatment Market: Treatment Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Lymphedema Treatment Market: Treatment Type Movement Analysis
  • 5.3. Global Lymphedema Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million/Billion)
  • 5.4. Conservative/Non-invasive Therapy
    • 5.4.1. Conservative/non-invasive therapy market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.4.2. Compression garments & stockings
      • 5.4.2.1. Compression garments & stockings market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.4.3. Compression bandages & wraps
      • 5.4.3.1. Compression bandages & wraps market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.4.4. Manual lymphatic drainage (MLD)
      • 5.4.4.1. Manual lymphatic drainage (MLD) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.4.5. Therapeutic exercise & complete decongestive therapy (CDT)
      • 5.4.5.1. Therapeutic exercise & complete decongestive therapy (CDT) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.4.6. Kinesiology taping
      • 5.4.6.1. Kinesiology taping market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.5. Medical devices
    • 5.5.1. Medical devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.5.2. Sequential pneumatic compression devices (SPCDs)
      • 5.5.2.1. Sequential pneumatic compression devices (SPCDs) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.5.3. Low-level laser therapy (LLLT) devices
      • 5.5.3.1. Low-level laser therapy (LLLT) devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.5.4. Advanced compression systems
      • 5.5.4.1. Advanced compression systems market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.6. Surgical interventions
    • 5.6.1. Surgical interventions market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.6.2. Lymphovenous anastomosis (LVA)
      • 5.6.2.1. Lymphovenous anastomosis (LVA) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.6.3. Vascularized lymph node transfer (VLNT)
      • 5.6.3.1. Vascularized lymph node transfer (VLNT) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
    • 5.6.4. Liposuction & debulking procedures
      • 5.6.4.1. Liposuction & debulking procedures market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 5.7. Pharmacological therapy
      • 5.7.1.1. Pharmacological therapy market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 6. Lymphedema Treatment Market: Affected Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Lymphedema Treatment Market: Affected Area Movement Analysis
  • 6.3. Global Lymphedema Treatment Market Size & Trend Analysis, by Affected Area, 2021 to 2033 (USD Million/Billion)
  • 6.4. Upper Extremity Lymphedema
    • 6.4.1. Upper extremity lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 6.5. Lower Extremity Lymphedema
    • 6.5.1. Lower extremity lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 6.6. Head & Neck Lymphedema
    • 6.6.1. Head & neck lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 6.7. Genital & Truncal Lymphedema
    • 6.7.1. Genital & truncal lymphedema market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 7. Lymphedema Treatment Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Lymphedema Treatment Market: End Use Movement Analysis
  • 7.3. Global Lymphedema Treatment Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million/Billion)
  • 7.4. Hospitals
    • 7.4.1. Hospitals market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 7.5. Lymphedema Treatment Centers & Rehabilitation Clinics
    • 7.5.1. Lymphedema treatment centers & rehabilitation clinics market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 7.6. Ambulatory Surgical Centers (ASCs)
    • 7.6.1. Ambulatory surgical centers (ASCs) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
  • 7.7. Homecare Settings
    • 7.7.1. Homecare settings market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 8. Lymphedema Treatment Market: Regional Estimates & Trend Analysis by Type, Affected Area, Treatment Type, and End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 8.3. North America
    • 8.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million/Billion)
    • 8.3.2. U.S.
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Competitive scenario
      • 8.3.2.3. Regulatory framework
      • 8.3.2.4. Reimbursement scenario
      • 8.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
    • 8.3.3. Canada
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Competitive scenario
      • 8.3.3.3. Regulatory framework
      • 8.3.3.4. Reimbursement scenario
      • 8.3.3.5. Canada market estimates and forecasts, 2021 - 2033
    • 8.3.4. Mexico
      • 8.3.4.1. Key country dynamics
      • 8.3.4.2. Competitive scenario
      • 8.3.4.3. Regulatory framework
      • 8.3.4.4. Reimbursement scenario
      • 8.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Competitive scenario
      • 8.4.1.3. Regulatory framework
      • 8.4.1.4. Reimbursement scenario
      • 8.4.1.5. UK market estimates and forecasts, 2021 - 2033
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory framework
      • 8.4.2.4. Reimbursement scenario
      • 8.4.2.5. Germany market estimates and forecasts, 2021 - 2033
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory framework
      • 8.4.3.4. Reimbursement scenario
      • 8.4.3.5. France market estimates and forecasts, 2021 - 2033
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory framework
      • 8.4.4.4. Reimbursement scenario
      • 8.4.4.5. Italy market estimates and forecasts, 2021 - 2033
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Competitive scenario
      • 8.4.5.3. Regulatory framework
      • 8.4.5.4. Reimbursement scenario
      • 8.4.5.5. Spain market estimates and forecasts, 2021 - 2033
    • 8.4.6. Denmark
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Competitive scenario
      • 8.4.6.3. Regulatory framework
      • 8.4.6.4. Reimbursement scenario
      • 8.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Competitive scenario
      • 8.4.7.3. Regulatory framework
      • 8.4.7.4. Reimbursement scenario
      • 8.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
    • 8.4.8. Norway
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Competitive scenario
      • 8.4.8.3. Regulatory framework
      • 8.4.8.4. Reimbursement scenario
      • 8.4.8.5. Norway market estimates and forecasts, 2021 - 2033
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Competitive scenario
      • 8.5.1.3. Regulatory framework
      • 8.5.1.4. Reimbursement scenario
      • 8.5.1.5. Japan market estimates and forecasts, 2021 - 2033
    • 8.5.2. India
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. Reimbursement scenario
      • 8.5.2.5. India market estimates and forecasts, 2021 - 2033
    • 8.5.3. China
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory framework
      • 8.5.3.4. Reimbursement scenario
      • 8.5.3.5. China market estimates and forecasts, 2021 - 2033
    • 8.5.4. South Korea
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory framework
      • 8.5.4.4. Reimbursement scenario
      • 8.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
    • 8.5.5. Australia
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory framework
      • 8.5.5.4. Reimbursement scenario
      • 8.5.5.5. Australia market estimates and forecasts, 2021 - 2033
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory framework
      • 8.5.6.4. Reimbursement scenario
      • 8.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Competitive scenario
      • 8.6.1.3. Regulatory framework
      • 8.6.1.4. Reimbursement scenario
      • 8.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. Reimbursement scenario
      • 8.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Competitive scenario
      • 8.7.1.3. Regulatory framework
      • 8.7.1.4. Reimbursement scenario
      • 8.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. Reimbursement scenario
      • 8.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory framework
      • 8.7.3.4. Reimbursement scenario
      • 8.7.3.5. UAE market estimates and forecasts, 2021 - 2033
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Competitive scenario
      • 8.7.4.3. Regulatory framework
      • 8.7.4.4. Reimbursement scenario
      • 8.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
    • 9.2.1. Innovators
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Tactile Medical
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. medi GmbH & Co. KG
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. SIGVARIS GROUP
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. BIOCOMPRESSION SYSTEMS
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. AIROS Medical, Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. L&R Group
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Huntleigh Healthcare Limited (Getinge AB)
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Koya Medical
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. 3M (Solventum)
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Juzo
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. JOBST (Essity)
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. ImpediMed Limited and ImpediMed Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Lympha Press (Mego Afek)
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
  • 9.4. Estimated Company Market Share Analysis, 2025
  • 9.5. List of Other Key Market Players
Show more
Product Code: GVR-4-68040-937-9

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America lymphedema treatment, by country, 2021 - 2033 (USD Million/Billion)
  • Table 4 North America lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 5 North America lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 6 North America lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 7 North America lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 8 U.S. lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 9 U.S. lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 10 U.S. lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 11 U.S. lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 12 Canada lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 13 Canada lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 14 Canada lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 15 Canada lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 16 Mexico lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 17 Mexico lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 18 Mexico lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 19 Mexico lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 20 Europe lymphedema treatment, by country, 2021 - 2033 (USD Million/Billion)
  • Table 21 Europe lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 22 Europe lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 23 Europe lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 24 Europe lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 25 UK lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 26 UK lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 27 UK lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 28 UK lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 29 Germany lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 30 Germany lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 31 Germany lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 32 Germany lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 33 France lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 34 France lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 35 France lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 36 France lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 37 Italy lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 38 Italy lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 39 Italy lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 40 Italy lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 41 Spain lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 42 Spain lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 43 Spain lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 44 Spain lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 45 Denmark lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 46 Denmark lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 47 Denmark lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 48 Denmark lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 49 Sweden lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 50 Sweden lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 51 Sweden lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 52 Sweden lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 53 Norway lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 54 Norway lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 55 Norway lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 56 Norway lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 57 Asia Pacific lymphedema treatment, by country, 2021 - 2033 (USD Million/Billion)
  • Table 58 Asia Pacific lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 59 Asia Pacific lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 60 Asia Pacific lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 61 Asia Pacific lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 62 China lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 63 China lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 64 China lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 65 China lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 66 Japan lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 67 Japan lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 68 Japan lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 69 Japan lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 70 India lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 71 India lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 72 India lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 73 India lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 74 South Korea lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 75 South Korea lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 76 South Korea lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 77 South Korea lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 78 Australia lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 79 Australia lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 80 Australia lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 81 Australia lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 82 Thailand lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 83 Thailand lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 84 Thailand lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 85 Thailand lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 86 Latin America lymphedema treatment, by country, 2021 - 2033 (USD Million/Billion)
  • Table 87 Latin America lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 88 Latin America lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 89 Latin America lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 90 Latin America lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 91 Brazil lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 92 Brazil lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 93 Brazil lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 94 Brazil lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 95 Argentina lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 96 Argentina lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 97 Argentina lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 98 Argentina lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 99 Middle East & Africa lymphedema treatment, by country, 2021 - 2033 (USD Million/Billion)
  • Table 100 Middle East & Africa lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 101 Middle East & Africa lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 102 Middle East & Africa lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 103 Middle East & Africa lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 104 South Africa lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 105 South Africa lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 106 South Africa lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 107 South Africa lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 108 Saudi Arabia lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 109 Saudi Arabia lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 110 Saudi Arabia lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 111 Saudi Arabia lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 112 UAE lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 113 UAE lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 114 UAE lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 115 UAE lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)
  • Table 116 Kuwait lymphedema treatment, by type, 2021 - 2033 (USD Million/Billion)
  • Table 117 Kuwait lymphedema treatment, by treatment type, 2021 - 2033 (USD Million/Billion)
  • Table 118 Kuwait lymphedema treatment, by affected area, 2021 - 2033 (USD Million/Billion)
  • Table 119 Kuwait lymphedema treatment, by end use, 2021 - 2033 (USD Million/Billion)

List of Figures

  • Fig. 1 Lymphedema treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market summary (2025)
  • Fig. 10 Penetration & growth prospect mapping
  • Fig. 11 Reimbursement pathway
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 Lymphedema treatment market: Type movement analysis
  • Fig. 17 Lymphedema treatment market type outlook: Key takeaways
  • Fig. 18 Secondary lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 19 Cancer-related lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 20 Non-cancer-related lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 21 Primary lymphedema, market, 2021 - 2033 (USD Million/Billion)
  • Fig. 22 Lymphedema treatment market: Treatment type movement analysis
  • Fig. 23 Lymphedema treatment market treatment type outlook: Key takeaways
  • Fig. 24 Conservative/Non-invasive Therapy market, 2021 - 2033 (USD Million/Billion)
  • Fig. 25 Compression Garments & Stockings market, 2021 - 2033 (USD Million/Billion)
  • Fig. 26 Compression Bandages & Wraps market, 2021 - 2033 (USD Million/Billion)
  • Fig. 27 Manual Lymphatic Drainage (MLD) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 28 Therapeutic Exercise & Complete Decongestive Therapy (CDT) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 29 Kinesiology Taping market, 2021 - 2033 (USD Million/Billion)
  • Fig. 30 Medical Devices market, 2021 - 2033 (USD Million/Billion)
  • Fig. 31 Sequential Pneumatic Compression Devices (SPCDs) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 32 Low-Level Laser Therapy (LLLT) Devices market, 2021 - 2033 (USD Million/Billion)
  • Fig. 33 Advanced Compression Systems market, 2021 - 2033 (USD Million/Billion)
  • Fig. 34 Surgical Interventions market, 2021 - 2033 (USD Million/Billion)
  • Fig. 35 Lymphovenous Anastomosis (LVA) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 36 Vascularized Lymph Node Transfer (VLNT) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 37 Liposuction & Debulking Procedures market, 2021 - 2033 (USD Million/Billion)
  • Fig. 38 Pharmacological Therapy market, 2021 - 2033 (USD Million/Billion)
  • Fig. 39 Lymphedema treatment market: Affected area movement analysis
  • Fig. 40 Lymphedema treatment market Affected area outlook: Key takeaways
  • Fig. 41 Upper Extremity Lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 42 Lower Extremity Lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 43 Head & Neck Lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 44 Genital & Truncal Lymphedema market, 2021 - 2033 (USD Million/Billion)
  • Fig. 45 Lymphedema treatment market: End use movement analysis
  • Fig. 46 Lymphedema treatment market end use outlook: Key takeaways
  • Fig. 47 Hospitals market, 2021 - 2033 (USD Million/Billion)
  • Fig. 48 Ambulatory Surgical Centers (ASCs) market, 2021 - 2033 (USD Million/Billion)
  • Fig. 49 Lymphedema Treatment Centers & Rehabilitation Clinics market, 2021 - 2033 (USD Million/Billion)
  • Fig. 50 Homecare settings market, 2021 - 2033 (USD Million/Billion)
  • Fig. 51 Regional Outlook, 2025 & 2033
  • Fig. 52 Regional market: Key takeaways
  • Fig. 53 North America lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 54 U.S. lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 55 Canada lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 56 Mexico lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 57 Europe lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 58 UK lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 59 Germany lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 60 France lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 61 Italy lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 62 Spain lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 63 Sweden lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 64 Denmark lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 65 Norway lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 66 Asia Pacific lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 67 Japan lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 68 China lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 69 India lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 70 Australia lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 71 South Korea lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 72 Thailand lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 73 Latin America lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 74 Brazil lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 75 Argentina lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 76 Middle East & Africa lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 77 South Africa lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 78 Saudi Arabia lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 79 UAE lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 80 Kuwait lymphedema treatment market, 2021 - 2033 (USD Million/Billion)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!